Shire Daytrana ADHD Patch To Launch In Early July With Some Class Labeling
Executive Summary
Shire and manufacturing partner Noven expect an early July launch for Daytrana, the first transdermal patch for the treatment of attention deficit/hyperactivity disorder to receive FDA approval
You may also be interested in...
Shire Expects Intuniv Launch In Mid-’09, As Firm’s ADHD Share Tops 30%
Shire plans to launch its nonstimulant ADHD candidate Intuniv in the second half of 2009, though new studies may be required to gain FDA approval
Shire Expects Intuniv Launch In Mid-’09, As Firm’s ADHD Share Tops 30%
Shire plans to launch its nonstimulant ADHD candidate Intuniv in the second half of 2009, though new studies may be required to gain FDA approval
ADHD Class Warnings Could Be Strengthened Pending FDA Research
Despite FDA's recent approval of class warning language for attention deficit/hyperactivity disorder treatments, the agency will continue research in an effort to better characterize the extent of stimulant side effects in ADHD patients, Division of Psychiatry Products Director Thomas Laughren indicated